Zevra Therapeutics posts results for Phase 2 SDX trial in idiopathic hypersomnia
A registry update shows results posted for a completed Phase 2 study testing serdexmethylphenidate against placebo in idiopathic hypersomnia patients.
The week's registry activity centers on a single completed Zevra Therapeutics study reaching the results-posted stage.
- **Serdexmethylphenidate (SDX), Phase 2, idiopathic hypersomnia**: Results were posted on 2026-06-30 for this randomized withdrawal study, which was sponsored by Zevra Therapeutics with Rho, Inc. as a collaborator1. The trial had an actual primary completion date of 2024-02-28 and study completion of 2024-03-211, and enrolled 66 participants1. The design used a 5-week open-label titration period followed by a 2-week double-blind withdrawal period, with two-thirds of participants continuing SDX and one-third switching to placebo1, and the primary outcome was change from baseline in Epworth Sleepiness Scale score, which ranges from 0 to 24 with higher scores indicating worse sleepiness1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.